Paper

LRRK2 kinase inhibitors induce a reversible effect in the lungs of non-human primates with no measurable pulmonary deficits

Ellis, Michael, Yu, Hongshi, Yin, Zhizhang, Merchant, Kalpana, Markgraf, Carrie, Houle, Christopher, Estrada, Anthony, Liu, Xingrong, Royer, Christopher, Sherer, Todd, Hirst, Warren, Hong, Mei, Baptista, Marco, Fell, Matthew, Ploch, Stephen, Steyn, Stefan, Barrett, Ted, Kennedy, Matthew, Rudolph, Karin, Fuji, Reina, Hill, Sue, Maddess, Matthew, Henry, Anastasia, Wang, Xiang, Bryce, Dianne, Sharma, Alok, Trost, Craig, Galatsis, Paul, Meier, William, Fiske, Brian, Stepan, Antonia

2018

Overview

Putative gain-of-function mutations in leucine-rich repeat kinase 2 (LRRK2), resulting in increased kinase activity and cellular toxicity, are a leading genetic cause of Parkinson's disease (PD). Hence, there is strong interest in developing LRRK2 kinase inhibitors as a disease-modifying therapy. Published reports that repeat dosing with two LRRK2 kinase inhibitors (GNE-7915 and GNE-0877) induce histopathological changes in the lung of non-human primates Fuji et al. 2015 raised concerns about potential safety liability of LRRK2 kinase inhibitors. In the present study, we sought to determine whether previously observed effects in the lung: (a) represent on-target pharmacology, but with the potential for margin of safety, (b) are reversible upon drug withdrawal, and (c) are associated with pulmonary function deficits. To this end, we evaluated the histopathological effects, toxicokinetics and target inhibition of three structurally diverse LRRK2 kinase inhibitors, GNE-7915 (30 mg/kg, BID, as a positive control), MLi-2 (15 and 50 mg/kg, QD) and PFE-360 (3 and 6 mg/kg, QD) following 2 weeks of dosing in non-human primates. Subsets of animals dosed with GNE-7915 or MLi-2 were evaluated after 2-week dose-free periods. All three LRRK2 kinase inhibitors induced mild cytoplasmic vacuolation of type II pneumocytes, as reported previously, confirming an on-target effect of these compounds. Interestingly, despite lower doses of both PFE-360 and MLi-2 producing nearly complete inhibition of LRRK2 kinase activity in the brain as assessed by levels of pS935-LRRK2, histopathological changes in lung were absent in animals treated with low-dose PFE-360 and observed only sporadically in the low-dose MLi-2 group. The lung effect was fully reversible at 2 weeks post-dosing of GNE-7915. In a second study of identical dosing with MLi-2 and GNE-7915, no deficits were observed in a battery of translational pulmonary functional tests. In aggregate, these results do not preclude the development of LRRK2 kinase inhibitors for clinical investigation in Parkinson's disease.

• Publisher: Cold Spring Harbor Laboratory Press,Cold Spring Harbor Laboratory
• Subject: Cyclin-dependent kinases / Kinases / Leucine / LRRK2 protein / Lungs / Movement disorders / Neurodegenerative diseases / Neurotoxicity / Parkinson's disease / Parkinsons disease / Pharmacology and Toxicology / Pneumocytes / Protease inhibitors